Biopharmaceutical plants use the concepts of pharmaceutical Engineering. They deal with the production of active medicines by applying the concepts of new and emerging technology that is biotechnology. Some of the living organisms such as plants are great source of raw-materials used to develop important medicines. Biopharmaceutical industries deal with such organisms and the botanical sources that don’t have any sorts of side-effects.

The demand for therapeutic proteins that have high healing capacity is increasing day by day. The biotechnology market has undergone rapid growth and expansion since its emergence about some years ago. A huge profit has been obtained from the growth hormones, human insulin and red-blood-cell stimulating agents. Introduction of these agents have rapidly accelerated the R&D and the global market in targeting a wider range of diseases, from growth deficiency to arthritis, multiple sclerosis and orphan diseases.

Around 80 biopharmaceutical plants already exist in the market and more than 500 are under their varied development stage at different clinical level. Among these biopharmaceuticals, the recombinant antibodies (rAbs) and their derivative are getting better clinical uses. Advancements made in the field of biotechnology have enabled the development of fully human antibodies, with improved therapeutic abilities. Therapeutic monoclonal antibodies (Mabs) have massive potential and accounts for about 40% of total production of biopharmaceutical products. These have wide range of clinical applications and have been identified very important in cancer and other chief medical areas such as several transplants, auto-immunity and various cardiovascular disorders.

A lot of success has been gained by these biopharmaceutical plants in the medical world but they are still thriving hard to contribute more and more towards the mankind.